Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Breast Cancer
Interventions
DRUG

Gemcitabine

DRUG

Adriamycine

DRUG

Paclitaxel

Trial Locations (10)

15006

Complejo Hospitalario Unviesitario A Coruña, A Coruña

23007

Complejo Hospitalario de Jaén, Jaén

28006

Hospital Universitario La Princesa, Madrid

28034

Hospital Universitario Ramón y Cajal, Madrid

28922

Hospital Universitario Fundación Alcorcón, Alcorcón

39008

Hospital Universitario Marqués de Valdecilla, Santander

46014

Hospital General Universitario de Valencia, Valencia

50009

Hospital Universitario Miguel Servet, Zaragoza

08916

Hospital Universitario Germans Trias i Pujol, Badalona

06080

Hospital Infanta Cristina, Badajoz

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Spanish Breast Cancer Research Group

OTHER

NCT00128856 - Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients | Biotech Hunter | Biotech Hunter